论文部分内容阅读
目的观察示踪减影透视(TSF)下超选择栓塞治疗原发性肝癌的效果。方法 102例不能手术切除的原发性肝癌患者按随机化分组表分为基线资料均衡的观察组与对照组各51例,分别采用TSF技术超选择栓塞治疗及非TSF超选择栓塞治疗,对2组甲胎蛋白(AFP)、肿瘤大小和1、2年的生存率进行观察对比。结果观察组采用TSF技术后肿瘤血管内超选择栓塞治疗成功率为100%(51/51),对照组非TSF栓塞治疗成功率仅为27.4%(14/51)(P<0.01);观察组患者的AFP水平由术前的(51.5±1.5)μg/L下降至(2.6±0.5)μg/L(P<0.01),肿瘤直径由术前的(10.1±1.5)cm缩小为(5.3±0.5)cm(P<0.01);且均低于对照组治疗后〔(10.3±1.3)μg/L、(7.3±1.5)cm,P均<0.01〕;观察组1、2年生存率(90.20%、72.55%)高于对照组(41.18%、21.56%,P均<0.01)。结论应用TSF技术可提高原发型肝癌介入治疗超选择栓塞的成功率,抑制肿瘤细胞生长,提高介入治疗疗效。
Objective To observe the effect of transcatheter embolization in the treatment of primary liver cancer under tracer subtraction fluoroscopy (TSF). Methods A total of 102 patients with unresectable primary liver cancer were randomized into two groups according to the randomized grouping table: 51 patients in observation group and control group with baseline data equalization, respectively, TSF superselective embolization and non-TSF superselective embolization, Group AFP (AFP), tumor size and 1, 2 year survival rate were observed and compared. Results The success rate of endovascular superselective embolization with TSF was 100% (51/51) in the observation group and 27.4% (14/51) in the non-TSF embolization group (P <0.01). The observation group The level of AFP decreased from (51.5 ± 1.5) μg / L to (2.6 ± 0.5) μg / L preoperatively (P <0.01), and the diameter of tumor decreased from (10.1 ± 1.5) cm to ) were significantly lower than those in the control group 〔(10.3 ± 1.3) μg / L, (7.3 ± 1.5) cm, P <0.01〕. The 1-year and 2-year survival rates of the observation group were 90.20% , 72.55%) higher than the control group (41.18%, 21.56%, P <0.01). Conclusion The application of TSF can improve the success rate of superselective embolization in interventional treatment of primary hepatocellular carcinoma, inhibit the growth of tumor cells and improve the efficacy of interventional therapy.